A Study of Oral Foralumab in Participants With Moderate to Severely Active Crohn's Disease

Summary

The primary objective of this study is to establish the safety and tolerability of multiple ascending doses (MAD) of foralumab enteric coated capsules administered orally, once daily for 5 days per week over 2 weeks in participants with moderate to severely active Crohn's Disease (CD).

Timeline

Start

2022-05-01

Primary completion

2023-07-07

Completion

2023-11-07

Drugs

Indications